Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Zegalogue

Chemical Namedasiglucagon
Dosage FormInjection (subcutaneous; 0.6 mg/0.6 mL)
Drug ClassAntihypoglycemic agents
SystemBlood
CompanyZealand Pharma
Approval Year2021

Indication

  • For the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above
Last updated on 3/14/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zegalogue (dasiglucagon) Prescribing Information.2021Zealand Pharma A/S, 2860 Søborg, Denmark
Document TitleYearSource
A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy and safety of dasiglucagon in rescue treatment of hypoglycemia in subjects with Type 1 Diabetes Mellitus compared to placebo and with reference to GlucaGen.2020Zealand Pharma
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with Type 1 Diabetes Mellitus (T1DM) compared to placebo.2020Zealand Pharma
Phase 3, randomized, double-blind, placebo/active-controlled, parallel-arm trial to assess efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo/GlucaGen® as rescue therapy for severe hypoglycemia in children with T1DM treated with insulin.2020Zealand Pharma